GSK previewed the data at AASLD in the fall, and the disclosure of an imbalance in thromboembolic events and deaths sent LGND shares cratering to as low as ~10.50. LGND recovered to ask high as nearly 19 before settling back recently. The full abstract release today doesn't seem to be causing an undue LGND sell-off (down 4.6% on higher than average volume) on a bad market day for most biotechs.
See below for the full abstract.